To address the need for effective medications to aid in the treatment of methamphetamine (METH) abuse, we used a nanotechnology approach to customize the in vivo behavior of an anti-METH single chain antibody (scFv7F9Cys). Anti-METH scFv7F9Cys was conjugated to dendrimer nanoparticles via a polyethylene glycol (PEG) linker to generate high-order conjugates termed dendribodies. We found that the high affinity (K D = 6.2 nM) and specificity for METH was unchanged after nanoparticle conjugation. The dendribodies were administered in an i.v. bolus to male Sprague Dawley rats after starting a s.c. infusion of METH. The PCKN values for clearance and volume of distribution of scFv7F9Cys after conjugation to dendrimers decreased 45 and 1.6-fold respectively, and the terminal elimination half-life increased 20-fold. Organ distribution of scFv7F9Cys and dendribody in blood and urine agreed well with the PCKN data. Renal clearance appeared to be the major route of elimination for both experimental medications. We have thus successfully developed a novel multivalent METH-binding nanomedicine by conjugating multiple anti-METH scFvs to dendrimer nanoparticles, extending the scFv half-life from 1.3 (±0.3) to 26 (±2.6) hr. These data suggest that the dendribody design could be a feasible platform for generating multivalent antibodies with customizable PCKN profiles.
. Here we report that the PCKN profile and efficacy of an anti-METH scFv7F9Cys was extended by conjugating it to a dendrimer delivery system. The dendrimer conjugated scFv7F9Cys exhibited prolonged activity in vivo due to increased residence time compared to the unconjugated scFv7F9Cys, mainly due to reduced clearance (Cls).
With the rise of antibody fragments and alternative binding scaffolds devoid of Fc binding regions, various strategies to increase the t 1/2 of these proteins have been developed 7, 8 . There are two major approaches that have been used to alter the PCKN of scFv molecules. The first is multimerization using recombinant manipulation, however scFvs tend to self-associate in unpredictable mixtures of dimers, trimers, and larger molecular weight complexes leading to production issues and poor reproducibility of the therapeutic properties. The second is chemical conjugation to a PEG chain. This strategy does extend the in vivo half-life but does not increase the binding valency of the scFv, nor its potency 9, 10 . Conjugation to PEG has even been reported to cause a decrease in the affinity of some conjugated antibody fragments 11, 12 . Here we report a dendribody design that converts single METH binding scFv into a multivalent nanomedicine that in theory can bind multiple METH molecules 13 while significantly extending the PCKN half-life of the experimental medication.
Results and Discussion
We previously reported our anti-METH scFv6H4Cys as a prototype antibody fragment to demonstrate the initial synthesis feasibility of the dendribody platform 6 . However, for in vivo proof-of-principle evidence of efficacy of the dendribody platform we shifted to another of our high affinity anti-METH scFvs, scFv7F9Cys. This was done for two reasons 1) the chimeric anti-METH Ch-mAb7F9 successfully completed a Phase 1a safety study (NCT01603147), suggesting a clearer route to the clinic for this antibody fragment 14 , and 2) SDS-PAGE analysis showed that scFv7F9Cys also resulted in higher-order dendribodies (increased multivalency) compared to prototype scFv6H4Cys (Fig. 1a ) 6 . To prepare the scFv7F9Cys dendribodies for in vivo testing, the synthesis reactions were purified by size exclusion chromatography (SEC) to separate the dendribodies from unreacted scFv7F9Cys, PEG modified scFv7F9Cys, and dendrimers (Fig. 2a) . Dendribodies with higher numbers of scFv7F9Cys eluted from the column in early fractions followed by lower-order dendribodies. PEG modified and unreacted scFv7F9Cys eluted 24 :G3 dendrimer (reaction ratio 11:1), and (lane 3) dendribody conjugation reaction incubated at room temperature and synthesized in conjugation buffer adjusted to pH 6.4. The scFv7F9Cys dendrimer conjugation resulted in higher-order dendribodies with on average, seven scFv7F9Cys molecules conjugated per dendrimer nanoparticle. b In vitro hemolysis assay to determine the safety of the dendribody medication. G3 PAMAM dendrimers exhibit concentration dependent hemolysis, whereas PEG modified dendrimers, unconjugated prototype scFv6H4Cys, and dendribodies are non-hemolytic. PEG modified dendrimers, scFv6H4Cys, and dendribodies protected the erythrocytes from hemolysis better than the control buffer (phosphate buffer saline, PBS).
Scientific RepoRts | 5:12060 | DOi: 10.1038/srep12060 predominantly in the later fractions (Fig. 2b) . All fractions were analyzed by SDS-PAGE. The initial fractions of enriched dendribodies were pooled and concentrated and used for further studies (Fig. 2c) .
Previously, it has been reported that dendrimers with exposed cationic surface groups exert hemolytic effects 15 . Hemolysis results from a serious damage to the membrane lipid bilayer and loss of cell integrity. The surface membrane of erythrocytes is negatively charged under physiological conditions. It is hypothesized that through initial adhesion to the cell surface via electrostatic attraction dendrimers cause disruption by creating holes into the cell membrane 16 . However, it is known that PEG modification of PAMAM dendrimers masks the cationic groups resulting in reduced hemolytic toxicity compared with the non-PEG modified dendrimers 17, 18 . Based on reports of cytotoxic effects of dendrimers, especially higher generation PAMAM (G4-G6) dendrimers, we investigated the hemolytic activity of G3 PAMAM dendrimers and its conjugates on erythrocytes isolated from adult male Sprague-Dawley rats 15 . The PEG 24 modified G3 PAMAM dendrimers (700 μ g/mL) and scFv6H4Cys (1300 μ g/mL) concentration ranges used in the hemolysis studies were selected as these concentrations were used to synthesize the dendribodies. The dendribody concentration (400 μ g/mL) used in the assay is the actual concentration measured using the bicinchoninic acid (BCA) assay after reacting 700 μ g/mL PEG 24 modified G3 PAMAM dendrimers with 1300 μ g/mL scFv6H4Cys. The range of concentrations included the highest concentration of G3 PAMAM dendrimers that would be seen by tissues immediately after in vivo injection of the dendribodies. We found that native G3 PAMAM dendrimers were indeed hemolytic in a dose dependent manner, but were non-hemolytic after PEG modification or once converted to the dendribody format (Fig. 1b) [19] [20] [21] [22] . In order to determine if the scFv7F9Cys retained ligand-binding function upon dendrimer conjugation, in vitro functional saturation and competition binding assays were performed with METH and amphetamine (AMP), respectively. The affinities for [ 3 H]-METH as measured by the dissociation constant (K D ) were 6.2 and 3.2 nM for the scFv7F9Cys and dendribodies respectively (Fig. 3a) . The AMP affinity (as measured by the IC 50 ) were 8 and 4 μ M for the scFv7F9Cys and dendribodies, respectively (Fig. 3b) The scFv7F9Cys based dendribodies showed statistically significant two-fold improvement in affinity for METH and AMP (p < 0.05) with respect to unconjugated scFv7F9Cys. These results indicate that conjugation of an anti-METH scFv to PEG modified dendrimer nanoparticle improved in vitro affinity to its ligand.
To test the in vivo functionality and serum PCKN profiles of the dendribody we used an established rat model of chronic METH use. The average serum scFv7F9Cys and dendribody concentration-time profiles were biphasic curves that fit a two-compartment PCKN model (Fig. 4a) . PCKN parameters of the unconjugated scFv7F9Cys and dendribodies were determined. Cls and volume of distribution (Vd) of scFv7F9Cys upon conjugation to dendrimer nanoparticle decreased 43 and 1.6 fold respectively, whereas the terminal elimination half-life (t 1/2λz ) increased 20 fold (Table 1) . Based on the classic PCKN equation where t 1/2 is a function of Cls and Vd, the drastic improvement in the t 1/2 of scFv7F9Cys is primarily an effect of decreased Cls of scFv7F9Cys upon conjugation to dendrimers. The analysis of whole blood and serum at each time point revealed that scFv7F9Cys and dendribodies were limited to the serum compartment, with negligible protein association with the erythrocytes.
Antibody fragments are in general regarded as safe 5 . Anti-METH mAbs and prototype scFv6H4 in preclinical studies have shown no unfavorable effects up to 35 mg/kg 4 . However, since the dendribodies are an entirely new medication, all rats were observed frequently and regularly for signs of toxicity by monitoring general health, body weight, feeding behavior, hematocrit values, and by weighing and inspecting organs when animals were euthanized at the end of each study. All rats in the study maintained healthy body weight and no change in the food intake among the study groups was seen. Furthermore, macroscopic gross examination of the major organs revealed no anatomical localization or pathological changes. Thus, scFv7F9Cys and dendribodies appeared safe during the timeframe of these studies. Taken together, scFv7F9Cys and dendribodies had no observable toxic effects, agreeing with the in vitro hemolysis data and the safety studies published for the PEG modified dendrimers, a reaction intermediate that we used for conjugation.
In vivo tissue distribution studies were performed to determine the effect of change in the molecular mass of scFv7F9Cys in the dendribody format. We found that 7% of the injected dose per gram of tissue (ID/g) of the unconjugated scFv7F9Cys accumulated in the right kidney at 0.5 hr with negligible accumulation in the kidneys at 2 and 8 hr ( Supplementary Fig. 1a and b). It has been previously reported that the scFvs (~25 KDa) are rapidly filtered through kidneys, since the molecular weight cut-off (MWCO) for glomerular filtration is ~60-70 KDa. During this process scFvs are often re-absorbed by the kidney tubules and metabolized 23 . For the dendribody group, some splenic accumulation (0.6% of injected dose) was observed at early time points (Supplementary Fig 1b) , but no other significant differences in organ accumulation were observed.
In practice, it is generally considered that it takes 3 to 5 half-lives to completely remove a drug from the body, once the drug administration is discontinued. Thus t 1/2 can be used as an indirect measurement to quantify elimination via Cls. Interestingly, representative radioactivity of 110% (24 hr Fig. 2 ). These data agree well with the estimated t 1/2λz of scFv7F9Cys (1.3 ± 0.3 hr) and dendribodies (26 ± 2.6 hr) in rats. Considering the molecular mass of dendribodies and the percent-injected radioactivity cleared in urine, it seems pertinent that the dendribodies could be catabolized in vivo to smaller units. For both study groups, the appearance of radioactivity in urine over time correlated well with its disappearance from blood suggesting that, for both therapeutics, renal clearance could be the major route of elimination. Overall, the blood, organ, and urine distribution of scFv7F9Cys and dendribodies correspond well with the PCKN data.
One measure of in vivo efficacy of the anti-METH mAbs is their ability to quickly and specifically bind METH and quickly redistribute it back to the vasculature. The average serum METH concentration over time curves showed that both scFv7F9Cys and dendribodies redistributed METH to the vascular compartment to cause an immediate 61 and 63 fold increase in the METH concentrations respectively compared to the control group (Fig. 4b) . However the dendribodies maintained higher serum METH concentrations for 96 hr compared to 8 hr by scFv7F9Cys (Fig. 4b) .
It has been previously shown that the anti-METH mAb-bound METH tends to adopt the PCKN profile of the mAb itself and thus the t 1/2 of METH appeared to increase in the dendribody treated rats. When METH concentrations in the presence of scFv7F9Cys and dendribodies were plotted as their respective molar concentrations, the relationship was nearly 1:2 ( Supplementary Fig. 3 ). This could be due to a certain population of scFv7F9Cys and dendribody administered that could have been inactive or inactivated in vivo over time. Nevertheless, we noticed that the serum METH area under the concentration versus time curve (AUC 0-last ) for dendribodies increased 15-fold compared to scFv7F9Cys treated rats. Thus suggesting that the Cls of METH was decreased in the presence of dendribodies compared with scFv7F9Cys treated rats. Overall the dendribody format prolonged the ability of scFv7F9Cys to bind METH in vivo over a period of 96 hr. We anticipate that this improved efficacy could result in some neuroprotective effect against METH induced adverse effects in further studies. In conclusion, this proof-of-concept study provides in vivo evidence that PCKN properties and efficacy of an anti-METH scFv can be improved by creatively combining molecular engineering and nanotechnology. Additionally, this dendribody platform capable of generating multivalent medications with customizable PCKN profiles could be adapted to increase the serum residence time for other biological therapies for various diseases and organ-specific targeting. In vitro hemolysis assay. Erythrocytes isolated from the blood of adult male Sprague Dawley rats were suspended in phosphate buffered saline (PBS buffer: 2.68 mM KCl, 1.47 mM KH 2 PO 4 , 136.89 mM NaCl, 8.10 mM Na 2 HPO 4 , pH 7.3), or PBS buffer containing G3 PAMAM dendrimers (concentrations ranging from 5 to 1000 μ g/ml), PEG 24 modified G3 PAMAM dendrimers (700 μ g/ml), scFv6H4Cys (1300 μ g/ml), and dendribodies (400 μ g/ml). These suspensions were placed in an incubator shaker at 37 °C for 4 hr. The erythrocyte suspensions were then centrifuged at 1000 g for 5 min. The percent hemolysis was determined on the basis of released hemoglobin in the supernatants measured spectrophotometrically at 540 nm. As a positive control erythrocytes were treated with distilled water and PBS was used as a negative control. The absorbance value obtained for the supernatant of the erythrocytes treated with distilled water was taken to indicate 100% hemolysis whereas PBS was considered 0% hemolytic.
PCKN Parameter
± SEM scFv7F9Cys Dendribodies Fold Change t 1/2λz (hr) 1.3 ± 0.3 26.6 ± 2.
Methods

Chemicals and drugs. Enzymes and
ScFv7F9Cys design, production, and purification. General molecular and genetic techniques for cDNA cloning and sequencing of scFv7F9Cys were performed as described in Sambrook and Russell, 2001 24 . A carboxyl terminus cysteine was engineered immediately following the 6His tag of scFv7F9 by DNA synthesis to create scFv7F9Cys. Catalent Pharma Solutions (Somerset, NJ) was contracted to transfect a Chinese hamster ovary (CHO) cell line for producing the recombinant scFv7F9Cys. Catalent utilized a proprietary transfection technology for introducing scFv7F9Cys cDNA into the CHO cells. ScFv7F9Cys CHO cells were stored in a liquid nitrogen cryo-freezer until thawed for cell culture. Under growth conditions optimized by Catalent Pharma Solutions, scFv7F9Cys was produced in gram quantities with cell culture using a Wave Bioreactor System (GE Healthcare, Piscataway, NJ). Briefly, under sterile conditions, scFv7F9Cys CHO cells were removed from liquid nitrogen storage, rapidly thawed in a 37 °C water bath, suspended in growth media, centrifuged at 250 g for 5 min, and the supernatant was decanted. The pelleted CHO cells were re-suspended in culture media and transferred to a 25 cm 2 static culture flask in a CO 2 incubator with 5% CO 2 and 95% humidity. Cell count and viability were monitored daily by staining small aliquots with trypan blue to detect lysed or apoptotic cells. Static cultures were expanded to 225 cm 2 flasks and cultured to a cell density of approximately 1 × 10 6 cells/ml with viability above 97%, reaching the exponential growth phase in 8 to 10 days, at which time 20 L Wave bioreactor bags were inoculated with 1.2 L CHO cell culture and 2 L fresh culture media to reach a starting cell count of > 3 × 10 5 cells/ml. The Wave bioreactor bags were incubated for 7 to 8 days with daily monitoring of cell counts, pH, ratios of partial pressure of carbon dioxide to partial pressure of oxygen (pCO 2 /pO 2 ), glucose, and lactate levels using a Bayer blood gas analyzer. Supplemental Cellboost media containing 3 mM glutamine was added on days 2, 4, and 6 to a maximum of 10 L total volume. Cells were harvested by centrifugation at 2800 g for 10 min when viability dropped below 50% and total living cell count was < 3 × 10 5 cells/ml. Culture supernatant containing secreted scFv7F9Cys was stored at − 80 °C until purification and formulation. To harvest and analyze total scFv7F9Cys expression, the samples were centrifuged at 20,000 g for 10 min, and the supernatant was analyzed using SDS− PAGE and Coomassie dye G-250 based GelCode Blue staining. The scFv7F9Cys expression product was purified using an AKTA explorer 100 FPLC system and a nickel sepharose IMAC HiPrep FF16/10 column (GE Healthcare, Piscataway, NJ) 4 .
Synthesis, scale-up, and purification of scFv7F9Cys based dendribodies. PEG 24 modified G3 PAMAM dendrimers were synthesized, characterized and further reacted with DTT reduced scFv7F-9Cys to produce dendribodies as previously described 6 . The dendribody reaction was scaled up in endotoxin-free plastic and glassware. The factors influencing the scFv6H4Cys based dendribody production were screened and optimized for a reaction volume of 0.07 ml. The production of scFv7F9Cys based dendribodies was scaled up to a 15 ml conjugation reaction. The dendribody reaction was scaled in eleven batches of 30 mg scFv7F9Cys per 15 ml batch. ScFv7F9Cys based dendribodies were purified by SEC using an AKTA Explorer 100 FPLC and a 350 ml Superdex 200/16 column (GE Healthcare, Piscataway, NJ). In brief, the column was equilibrated with 5 column volumes of molecular weight sizing buffer (20 mM sodium phosphate buffer, pH 7.4, 500 mM NaCl) at 2.5 ml/min. The dendribody reaction mixture containing the unreacted PEG 24 modified dendrimers and scFv7F9Cys, unconjugated scFv7F-9Cys, and dendribodies was loaded onto the column. The dendribodies were eluted from the column and collected as 0.5 ml fractions. The elution profile was monitored by UV absorbance at 220, 254, and 280 nm wavelengths. All fractions were analyzed by SDS− PAGE, and the dendribody-enriched fractions were pooled and concentrated. ScFv7F9cys and dendribody concentrations were estimated using micro BCA assay (Pierce Thermo Scientific, Waltham, MA) as per manufacturer's instructions.
Saturation and competition binding assays for determination of equilibrium dissociation constants (K D ) and half minimal inhibitory concentration (IC 50 ) values of scFv7F9Cys and scFv7F9Cys based dendribodies for METH and AMP respectively. The binding affinities (K D s) of scFv7F9Cys and dendribodies for METH were determined using a saturation binding assay as previously described for scFv6H4Cys and scFv6H4Cys based dendribodies 4, 6 . The AMP binding of scFv7F9Cys and scFv7F9Cys based dendribodies were evaluated using competition binding assays measuring IC 50 value as previously described 25 .
Tritium labeling of scFv7F9Cys and scFv7F9Cys based dendribodies. ScFv7F9Cys 3 H]-dendribodies were used as a tracer dose to allow accurate determination of scFv7F9Cys and dendribody concentrations over time in the rats. Briefly, 500 μ Ci of [ 3 H]-NSP was dried to remove solvents under a light stream of argon gas in a siliconized tube. The scFv7F9Cys or dendribodies (0.5-1 mg/500 μ l in PBS, pH 7.4) was added to the tube and then this solution was placed in the reaction vial along with a stir bar. The reaction was stirred for 4 hr on ice in the dark. The reaction mixture was then passed over a PD10 G-25 gel filtration column (GE Healthcare) that had been equilibrated with PBS to separate unincor- ]-dendribodies that were detected using absorbance at 280 nm were combined and dialyzed against PBS using 3 kDa MWCO Slide-A-Lysers (Thermo Fisher Scientific). These dialyzed [ Pharmacokinetic studies of scFv7F9Cys, scFv7F9Cys based dendribodies, and METH in rats. All methods were done in accordance with and approved by The Institutional Animal Care and Use Committee at University of Arkansas for Medical Sciences (UAMS). Detailed PCKN studies were designed with the following groups: control (vehicle), scFv7F9Cys, and dendribodies using dual jugular vein catheterized adult male Sprague-Dawley rats (n = 6 per group) purchased from Charles River Laboratories (Raleigh, NC). Animals were housed individually in a light-controlled environment (12 hr light/dark cycle). They received water ad libitum and were fed approximately 30 g of food pellets daily, which maintained their body weights between 280-310 g. All experiments were conducted with the prior approval of the Institutional Animal Care and Use Committee of UAMS. On day -4 (i.e., 4 days prior to dosing) of the study, pre-METH blood samples (150 μ l) were taken and on day -3, the rats received 3.2 mg/kg/day METH via subcutaneous Alzet 15 day osmotic pumps (Durect Corp, Cupertino, CA). On day -1, blood samples (150 μ l) were taken at 10 am, 1, and 5 pm to allow determination of METH control steady-state concentrations and the rats were placed in metabolic cages for urine and feces collection. On Day 0, the rats were given an i.v. bolus dose of anti-METH protein formulation of 36.5 mg/kg containing a tracer dose (~100 μ g) of 5 × 10 6 DPM [ 3 H]-protein or an equal volume of vehicle (formulation buffer without protein and tracer dose). This 36.5 mg/kg dose was calculated to be equimolar to the METH body burden at steady state. Immediately following administration of vehicle, scFv7F9Cys, or dendribodies, blood samples (150 μ l) were taken at various time points (1, 5, 10, 30 min; 1, 2, 4, 8, 24, 48, 72, 96, 120, 144 , and 168 hr) until radioactivity detected in these samples was near background levels. A small aliquot of whole blood was used to determine the hematocrit values (the proportion of the blood volume occupied by erythrocytes) in heparinized tubes using standard procedures every day of the study. As indicators of medication safety, rats were continuously monitored for general health, hematocrit values, body weight, feeding behavior and at the end of the study after euthanasia, their major organs were weighed and visually inspected for signs of toxicity.
ScFv7F9Cys and dendribody blood to serum ratios were determined using blood samples collected during the PCKN studies. Duplicate whole blood samples (5 μ l) were added to 5 ml liquid scintillation fluid (Ecoscint A, National Diagnostics, Atlanta, GA) for quantification by liquid scintillation spectrophotometry. The remaining blood was allowed to clot, centrifuged, and the serum fraction was collected. isoflurane (Forane ® , Baxter Heathcare Corporation, Deerfield, IL) and sacrificed by decapitation. Major organs (brain, heart, liver, kidney, spleen, pancreas and testes) were immediately collected, weighed and stored at − 80 °C along with serum samples until analysis. To determine the molar concentration of unlabeled scFv7F9Cys and dendribodies in the blood, the known amounts of Estimation of serum METH concentrations using liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis. For analysis of METH serum concentrations, Strata X-C 33 μ M Polymeric Strong Cation solid phase extraction columns (Phenomenex, Torrance, CA) were conditioned with 2 ml methanol and 2 ml loading buffer (100 mM NaPO 4 , pH 8.1). A METH standard curve in Sprague Dawley rat non-hemolyzed serum (Pel-Freez Biologics, Rogers, AR) with concentrations ranging from 0.3-2000 ng/ml and quality control standards were prepared for analysis of serum as previously described 29 . For each sample or standard, 25 μ l aliquots were mixed with 25 μ l of internal standard (100 ng/ml METH-D5) and allowed to equilibrate to precipitate proteins before 1 ml of loading buffer (50 mM sodium phosphate buffer, pH 6.7, 0.1 M sodium sulfate) was added. The mixture was then transferred to the solid phase extraction column and rinsed with methanol. After drying the column under vacuum, elution buffer [5% (v/v) ammonium hydroxide, 5% (v/v) tetrahydrofuran, and 90% (v/v) acetonitrile] was used to elute the METH into glass tubes containing 0.5 M hydrochloric acid. The samples were then dried under nitrogen gas, reconstituted with 0.1% (v/v) formic acid, and centrifuged to remove any potential precipitates. The concentrations of METH were then determined using an Acquity Ultra Performance Liquid Chromatography system interfaced with a Quattro Premier XE mass spectrometer (Waters Corp, Milford, MA). The analytes were separated using a linear binary gradient with reversed phase chromatography at a flow rate of 0. The column was maintained at 40 °C and coupled to an electrospray ionization probe, which was operated in the positive ion mode. Positive ions for METH and METH-D5 were generated at cone voltages of 18 and 21 volts, respectively. Product ions METH and METH-D5 were generated using argon collision induced disassociation at collision energy of 15 and 21 eV while maintaining a collision cell pressure of 3 × 10 −3 torr. Detection was achieved in the multiple-reaction-monitoring (MRM) mode using the precursor → product ions, m/z 149.8 → 90.8 and 155.2 → 91.5 for METH and METH-D5, respectively. The lower and upper limit of quantification for METH was 1 and 2000 ng/ml, respectively. All predicted values for standards were within ± 20% (Supplementary Fig. S4 ).
Biodistribution studies of scFv7F9Cys and scFv7F9Cys based dendribodies. At Data and statistical analysis. The saturation and competition binding data were analyzed by non-linear curve fitting using Graphpad PRISM ® 5.0d software. Affinity (K D ) for METH saturation binding was determined using nonlinear curve fitting that accounted for specific and nonspecific binding. IC 50 values for AMP binding to scFv7F9Cys and dendribodies were determined from the percent [ . Unpaired, one-tailed Student's t-test was performed to obtain the statistical significance of the differences in affinity values in K D (METH) and IC 50 (AMP) for scFv7F9Cys and dendribodies determined in buffer. Data represent mean ± standard error of the mean (SEM) for the number (n) of experiments indicated in figure legends. A significance level of p < 0.05 was used for all studies. All PCKN analyses were performed using WinNonlin version 5.0 (Pharsight Corporation, Mountain View, CA). Serum PCKN parameters were derived from model-dependent analysis of the average concentration versus time curves for scFv7F9Cys and dendribodies. A curve was fit to the data points using a two-compartment i.v. bolus model, with no weighting, 1/y, or 1/y 2 weighting. The best-fit line was chosen by visual inspection and analysis of the residuals. The PCKN calculations included t 1/2λz , Cls, and Vd at steady-state. To assess the effect of scFv7F9Cys and dendribodies on METH Scientific RepoRts | 5:12060 | DOi: 10.1038/srep12060 serum concentrations at each time point, a multiple comparison was performed using two-way analysis of variance (ANOVA) for three groups and Student's t-test for two groups. Statistical differences were set at the p < 0.05 levels. All tests were performed using Graphpad PRISM ® 6.0d software.
